NCT01201343View on ClinicalTrials.gov

Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

July 31, 2010

Study Completion Date

July 31, 2010

Conditions

Multiple Sclerosis, Relapsing, Remitting

Interventions

DRUG

Interferon beta-1a

All Listed Sponsors

collaborator

Merck Serono S.A.S, France

INDUSTRY

lead

Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT01201343 - Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients | Biotech Hunter | Biotech Hunter